Partnership for Cures

Our goal: funding the projects that, when successful, will catalyze follow-on funding and/or further trials and publications. We focus on patient access to viable treatments, regardless of whether there may be a philanthropic opportunity or commercial value to treat patients with unmet medical needs.

Cures Within Reach’s Repurposing Communities: Disease Areas, Geographies, Population Groups

In 2019, Cures Within Reach launched Repurposing Communities to provide strategic alignment among our many stakeholder groups within disease-specific and geographic areas of interests. Engagement by all our stakeholder groups can be enhanced within the specific community as well as through CWR central organization, including patient groups and disease associations, universities and research institutions, healthcare industry and service providers, philanthropy, and government / others.

In 2021, we expanded into population groups, adding Pediatrics, Veterans & Military, and Minority & Underserved (DEI) areas of interests.

Our Disease-Specific Communities
Neurology (including mental health and neurodegenerative)
Oncology
Rare diseases

Our Geographic-Specific Communities
Chicago
The Mid-Atlantic (includes Washington DC, VA, MD, DE and parts of PA)
The Developing World (includes low and lower-middle income countries, per the World Bank)

Our Patient Population Communities
Pediatrics
Veterans and Active Military
Minority and Underserved within Diversity, Equity & Inclusion (includes health disparities, patients and researchers)

For over a decade, Cures Within Reach has found and funded over 100 repurposing research projects in over 60 institutions in 60 different diseases. This has resulted in supporting research that found 13 repurposed therapies for children with deadly diseases ALPS and FD, adults with multiple sclerosis, lung cancer, blood cancer, myelodysplastic syndrome and prostate cancer, and adult and children with type 1 and type 2 diabetes. Our $7 million in funding has helped to catalyze more than $76 million in follow-on funding - a strong leverage metric. We have a strong platform called CureAccelerator™ where researchers and clinicians submit their clinical repurposing research ideas for funding.